JTE 952) manufacturers
- JTE-952
-
- $3100.00 / 100mg
-
2026-03-13
- CAS:1255303-54-8
- Min. Order:
- Purity:
- Supply Ability: 10g
- JTE-952
-
- $3100.00 / 100mg
-
2025-08-22
- CAS:1255303-54-8
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | JTE 952) Basic information |
| Product Name: | JTE 952) | | Synonyms: | JTE 952);JTE-952
(JTE952;Methanone, [3-[4-[(4-cyclopropylphenyl)methoxy]-3-methoxyphenyl]-1-azetidinyl][4-[[(2S)-2,3-dihydroxypropoxy]methyl]-2-pyridinyl]- | | CAS: | 1255303-54-8 | | MF: | C30H34N2O6 | | MW: | 518.6 | | EINECS: | | | Product Categories: | | | Mol File: | 1255303-54-8.mol |  |
| | JTE 952) Chemical Properties |
| Boiling point | 764.1±60.0 °C(Predicted) | | density | 1.294±0.06 g/cm3(Predicted) | | form | Solid | | pka | 13.54±0.20(Predicted) | | color | White to off-white |
| | JTE 952) Usage And Synthesis |
| Uses | JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis[1]. | | in vivo | JTE-952 (3 mg/kg, p.o. once-daily) treatment reduces the overall progression of the clinical score, including inflammation and bone erosion in mouse model of collagen-induced arthritis (CIA model)[1]. | Animal Model: | Mouse model of collagen-induced arthritis (CIA model)[1]. | | Dosage: | 3 mg/kg. | | Administration: | Oral once-daily. | | Result: | Reduced the overall progression of the clinical score, including inflammation and bone erosion. |
| | References | [1] Ikegashira K, et al. Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. Bioorg Med Chem Lett. 2019 Apr 1;29(7):873-877. DOI:10.1016/j.bmcl.2019.02.006 |
| | JTE 952) Preparation Products And Raw materials |
|